KDM1A and cancer: LSD1 inhibitors led to synergistic anti-cancer effects when combined with PARP inhibitors (olaparib, niraparib, rucaparib), leading to significant inhibition of the growth of tumors developed from HR-proficient (but not from HR-deficient) cells in experimental animals [208].